Providing investment to early-stage companies backed by strong entrepreneurs

Polar Light Ventures

Providing investment to early-stage companies backed by strong entrepreneurs

Polar Light Ventures

Polar Light Ventures focuses on Seed Stage
Technology Investments in Europe and the US, with outstanding entrepreneurs and highly scalable business models.

Polar Light Ventures focuses on Seed Stage
Technology Investments in Europe and the US, with outstanding entrepreneurs and highly scalable business models.

We actively support our founders
and portfolio companies to
achieve their goals by
leveraging our extensive
global network

What’s new in our portfolio

British digital health start-ups win in Las Vegas

LAS VEGAS, Oct. 13, 2023 (DIGITAL HEALTH) — A quartet of British digital health start-ups were named among the winners at the Digital Health Hub Awards at HLTH in Las Vegas on Monday…

Fresha accelerates global growth and expands into new markets with launch of platform in nine languages

LONDONAug. 22, 2023 /PRNewswire/ — Fresha, the world’s #1 booking platform, marketplace and payments system for beauty and wellness, today announced further acceleration of its growth in global marketplaces. Fresha is now available in nine languages…

eCurrency and CMA partner to provide an integrated CBDC – RTGS solution for Central Banks

Oakland, CA, June 26, 2023 (PR Newswire) – eCurrency Mint and CMA announced today that they are partnering to provide central banks an integrated Real Time Gross Settlement (RTGS) and eCurrency Central Bank Digital Currency (CBDC) solution…

Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, yesterday presented results from a long-term extension study, OA-07 for its knee OA drug candidate, lorecivivint…